Paula Green Sells 294 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 294 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $165.49, for a total value of $48,654.06. Following the completion of the transaction, the senior vice president owned 116,720 shares in the company, valued at $19,315,992.80. The trade was a 0.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $6.10 during trading on Wednesday, hitting $158.50. The company’s stock had a trading volume of 2,133,311 shares, compared to its average volume of 1,563,605. The business has a fifty day moving average of $121.94 and a 200-day moving average of $84.72. The company has a market cap of $9.94 billion, a PE ratio of -71.40 and a beta of 2.22. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $170.66. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 EPS. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Twist Bioscience in the 2nd quarter valued at about $600,191,000. William Blair Investment Management LLC bought a new position in Twist Bioscience during the second quarter worth about $223,722,000. Bank of America Corp DE bought a new position in Twist Bioscience during the second quarter worth about $94,922,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience in the first quarter worth about $22,563,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Twist Bioscience in the second quarter worth about $19,722,000.

Analysts Set New Price Targets

TWST has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Leerink Partners boosted their target price on shares of Twist Bioscience from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Thursday, September 17th. Finally, UBS Group assumed coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.